共 96 条
- [1] Cunningham D(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20
- [2] Allum WH(2020)Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma Ann N Y Acad Sci 1482 213-224
- [3] Stenning SP(2022)Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy Front Immunol 13 991-2021
- [4] Leng XF(2022)Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study Ann Transl Med 10 2013-550
- [5] Daiko H(2022)Safety and feasibility of esophagectomy following combined immunotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score matching analysis Front Immunol 13 546-842
- [6] Han YT(2022)Neoadjuvant immune checkpoint inhibitors plus chemotherapy in locally advanced esophageal squamous cell carcinoma: perioperative and survival outcomes Front Oncol 12 1-99
- [7] Mao YS(2021)Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma J Gastrointest Oncol 12 832-247
- [8] Qiao Y(2019)Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study JAMA Oncol 5 90-1357
- [9] Zhao C(2019)Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study J Clin Oncol 37 234-1631
- [10] Li X(2022)Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia ESMO Open 7 1351-2768